8
Years of research
A new standard for longevity supplements
Most companies sell supplements. NOVOS runs a longevity research program.
Mechanistic studiesAged-animal modelsPlacebo-controlled human research
Randomized human research found favorable effects over placebo across three measures of vascular function.
NOVOS Core
12 ingredients. 12 Hallmarks of Aging. One coordinated formulation.
7
Scientists and physicians involved in formulation
7
Whole-formulation studies
450+
Ingredient studies reviewed
2,000+
MDs and clinicians recommend NOVOS
15M+
NOVOS servings
Available at
Mayo Clinic StoreBumrungrad International HospitalErewhonEquinoxRemedy PlaceFour SeasonsSunLife Organics
Member of & selected for
Longevity Biotechnology AssociationHealthy Longevity Medicine SocietyXPRIZE Top 100 Healthspan Competition
Third-party tested. Retail availability does not imply institutional medical endorsement.
HEALTHSPAN DEFINED
Healthspan is how long your body keeps functioning well.
Lifespan is how long you live. Healthspan is how long the body’s major systems continue to function well. Because those systems age through interconnected processes, meaningful healthspan research must look beyond a single molecule, pathway, or biomarker.
Core was designed around the 12 Hallmarks of Aging, then studied from cellular mechanisms to aged-animal lifespan and human physiology.
Why Core is different
Aging doesn’t happen in one place.
Many supplements focus on one pathway, such as NAD+, cellular senescence, oxidative stress, or collagen. Each represents relevant biology. None represents the entire aging process.
Choose a strategy. One region lights up; the rest of the aging system remains.
Important biology?
Yes.
The whole aging process?
No.
Calling something a “longevity supplement” does not make it one.
A molecule can change.
For example, an increase in NAD+. That demonstrates biological activity. Not, by itself, an effect on healthspan or lifespan.
A biomarker can change.
That shows a measurable signal moved. Not, by itself, that someone will function better, age more slowly, or live longer.
Someone can feel different.
That matters in daily life, but does not establish that underlying biological aging changed. In fact, it's possible for something to make you feel better, but shorten healthspan and lifespan.
What has actually been studied?
Mechanistic research
Tests whether the formulation affects biological processes relevant to aging, including genomic stability, cellular senescence, stress resilience, and healthy inflammatory response.
Aged-animal research
Tests the complete formulation across whole-organism lifespan and functional-health outcomes.
Human biological aging research
In a small Core + Boost study, 8 of 11 participants had a lower DunedinPACE result at follow-up. There was no placebo group.
Placebo-controlled human clinical research
Tests the finished Core formulation against placebo using three measures of vascular function.
Follow the evidence from laboratory research to human trials
THE FIRST HUMAN HEALTHSPAN TEST
Why cardiovascular function was the first system we studied in humans.
Vascular function changes with age, affects tissues throughout the body, and can be evaluated with validated functional measurements.
AGE-SENSITIVE
Vascular function changes over time.
Arteries tend to become less flexible, endothelial responsiveness can decline, and systolic blood pressure commonly rises with age.
WHOLE-BODY RELEVANCE
Nearly every tissue depends on circulation.
Blood vessels deliver oxygen, nutrients, hormones, and metabolic signals to the brain, muscles, kidneys, skin, and other organs.
OBJECTIVELY MEASURABLE
Function can be tested in humans.
Systolic blood pressure, arterial flexibility, and endothelial function provide validated ways to evaluate vascular physiology.
Because vascular function changes with age, affects the whole body, and can be measured with validated endpoints, it was a practical first system in which to test NOVOS Core. However, NOVOS Core was not designed to target the cardiovascular system: it was designed to target the Hallmarks of Aging, with the hypothesis that it could have downstream positive effects on multiple organ systems. The cardiovascular system was the first studied, but there's reason to believe that the NOVOS Core formula will have a positive impact on additional systems in followup studies.
RANDOMIZED HUMAN RESEARCH
We tested the complete NOVOS Core formula.
In a six-month randomized, double-blind, placebo-controlled study of adults 40 and older, researchers tested the finished Core formulation across three complementary measures of vascular function.
- 6 MONTHS
- RANDOMIZED
- DOUBLE-BLIND
- PLACEBO-CONTROLLED
- ADULTS 40+
Publication status: Completing peer review process. Publication forthcoming.
The complete finished formula available for purchase is what was tested.
Three complementary measures of vascular function.
Systolic blood pressure (SBP)
The pressure exerted when the heart contracts, assessed in participants who began within a healthy range.
Arterial flexibility (PWV)
How quickly a pressure wave travels through the large arteries—a standard measure of arterial flexibility.
Endothelial function (FMD)
How effectively an artery widens when increased blood flow is required.
THREE HUMAN RESULTS
What the study found.
Healthy systolic blood pressure
6.1 mmHg placebo-adjusted difference
Among participants who began within a healthy range
Systolic blood pressure is the pressure exerted when the heart contracts.
Supports maintenance of healthy systolic blood pressure already within the normal range.
NOVOS Core6.1
Aerobic exercise4
HIIT3.9
Resistance training2.9
Sodium reduction (diet)2.4
Values shown as mmHg reduction.
Arterial flexibility (PWV)
1.2 m/s favorable difference
Versus placebo
Carotid-femoral pulse wave velocity is a standard measure of arterial flexibility.
Supports healthy arterial flexibility.
NOVOS Core1.2
HIIT0.63
Mediterranean diet0.02
Severe weight loss0.8
Values shown as m/s improvement.
Endothelial function (FMD)
+2.9 percentage points
Versus placebo
Flow-mediated dilation measures how effectively an artery expands when blood flow increases.
Supports healthy endothelial function.
NOVOS Core2.9
Resistance training2.11
Mediterranean diet1.3
Aerobic exercise1.2
Severe weight loss1.1
Values shown as % improvement.
Values shown in the stated unit and drawn from separate published studies in similar adult populations.
Randomized, double-blind, placebo-controlled human research. Outcomes were physiological biomarkers, not disease outcomes. Lifestyle comparisons are cross-study, not head-to-head, and involve different populations and protocols. NOVOS does not claim that Core is superior to healthy lifestyle practices, which remain foundational. Individual results vary.
See how these results compare with published single-ingredient trials →
SYSTEMATIC LITERATURE BENCHMARK
How unusual were the NOVOS Core cardiovascular results?
NOVOS reviewed randomized clinical research on commonly marketed heart-health supplement ingredients. Qualifying positive and null findings were retained, then compared with Core’s observed effects.
How often did published supplement trials produce effects as large as NOVOS Core?
Cross-study comparison, not head-to-head. Based on separate published studies with different populations and protocols.
From 3,388 records to the most comparable evidence.
Qualifying null findings retained
3,388PubMed records identified
147Qualifying randomized trials
171Study-marker comparisons
55Fasted comparisons used for the strictest like-for-like analysis
How the benchmark was built
- Population
- Apparently healthy adults under the methodology’s defined inclusion rules.
- Intervention
- A single supplement ingredient or standard form.
- Control
- Placebo or inert control.
- Outcomes
- Systolic blood pressure, arterial flexibility, or endothelial function.
- Analysis
- Placebo-adjusted between-group effects.
- Inclusion
- Statistical significance did not determine entry. Qualifying positive and null findings were retained.
- Outperformance rule
- Core exceeded a comparison when that comparison showed no statistically significant effect or a statistically significant effect smaller than Core’s benchmark.
- Limitation
- This methodology does not constitute a direct trial of the products in the same participants.
Why fasted comparisons were emphasized
Meals can temporarily affect vascular tone, blood flow, and blood-pressure measurements. Because Core’s sustained measurements were taken fasted, the strictest comparison also used fasted competitor measurements. This produced 55 comparisons. It does not eliminate every source of cross-study variability.
Across trials, Core set an unusually high bar.
BLOOD PRESSURE
Effect exceeded 94%
34 of 36 fasted comparisons
ARTERIAL FLEXIBILITY
Effect exceeded 100%
8 of 8 fasted comparisons
ALL THREE MEASURES
Effect exceeded 96%
Across the complete 171-comparison database
In this cross-study benchmark, Core’s observed effects exceeded most qualifying single-ingredient comparisons across the three measured vascular markers.
Cross-study comparison, not head-to-head. Based on separate published studies with different populations and protocols.
How did Core compare with the average published result?
Healthy blood pressure
NOVOS Core6.10 mmHg
Average published result2.53 mmHg
2.4x
Arterial flexibility
NOVOS Core1.18 m/s
Average published result0.43 m/s
2.7x
Endothelial function
NOVOS Core2.90 pp
Average published result2.44 pp
1.2x
In the wider arterial-flexibility analysis, Core’s observed effect exceeded all 12 qualifying comparisons.
Cross-study comparison, not head-to-head. Averages come from separate randomized studies with different participants and protocols. Individual results vary.
The human trial measured one system. Core was designed as a system.
The cardiovascular trial provides finished-product human evidence in one age-sensitive physiological system. Core was designed more broadly around the interconnected Hallmarks of Aging.
Synergy should be tested, not assumed.
In preclinical combination research, interventions may be synergistic, additive, neutral, less effective than the strongest individual intervention, or detrimental. That is why NOVOS evaluates Core as a complete formulation.
- 8% synergistic
- 31% additive
- 8% neutral
- 38% below the strongest individual intervention
- 15% shortened lifespan
ANIMAL LIFESPAN STUDY
A stack
- Ingredient A
- Ingredient B
- Ingredient C
- Ingredient D
- Ingredient E
Promising separately, but can behave completely differently when combined.
A system
- Hallmarks
- Physiology
- Finished-formula research
Designed together. Studied together.
Core was built by evaluating complementary biological pathways with longevity researchers—not by combining trendy ingredients.
Preclinical
The complete formula was also studied for lifespan and functional health.
Aged-animal modelComplete Core formulationLifespan and healthspan outcomes
Statistically significant favorable results for lifespan and functional health were observed in aged-animal models.
Animal studies can evaluate long-duration whole-organism outcomes that cannot practically be studied across a human lifespan. They do not establish that Core extends human lifespan.
Show me the science: aged-animal lifespan
Study type: aged-animal lifespan and healthspan research using the complete Core formulation.
Measured: median lifespan and functional-health measures.
Finding: where currently cleared for commercial display, an 18% greater median lifespan versus control was reported.
Does not prove: human lifespan extension or disease prevention.
Biological pace of aging
Preliminary human evidence using DunedinPACE.
DunedinPACE uses epigenetic patterns to estimate biological Pace of Aging. In a small, uncontrolled observational study of Core plus Boost, most participants had a lower result at follow-up.
73%
8 of 11 participants
Had a lower DunedinPACE result at follow-up
No placebo group. This preliminary study does not establish that participants aged more slowly, gained healthspan, or will live longer.
A healthspan routine should support life today, too.
Core contains ingredients individually studied in areas including energy, sleep, calm focus, mood, and skin health.
- Energy
- Sleep
- Calm focus
- Mood
- Skin
81%
of surveyed NOVOS customers reported feeling a difference after two weeks across six areas of wellbeing.
Energy · Sleep · Cognition · Mood · Skin · Overall wellbeing
Self-reported customer survey, not a randomized clinical trial. These subjective benefits were not measured in the Core randomized trial. Individual results vary.
The people behind the formulation
Built with people who study why we age.
Dr. George Church, PhD
Harvard Medical School and MIT
Genomics pioneer studying the genetics of aging and reprogramming.
Dr. Pamela Maher, PhD
Salk Institute and University of British Columbia
Neurobiologist studying plant compounds, cellular stress resilience, and brain aging.
Dr. J. Pedro de Magalhaes, PhD
Harvard Medical School
Biogerontologist researching the comparative biology and genetics of lifespan.
Dr. Diogo Barardo, PhD
NOVOS Head of R&D and University of Singapore
Longevity researcher focused on multi-pathway formulation design and evaluation.
Supplements are one part of healthspan.
Exercise, nutrition, sleep, metabolic health, stress management, social connection, and appropriate preventive care remain foundational.
- Exercise
- Nutrition
- Sleep
- Metabolic health
- Preventive care
- Stress management
- Social connection
The NOVOS Life app turns longevity science into personalized guidance spanning products, nutrition, exercise, sleep, measurement, and lifestyle.
NOVOS is a Public Benefit Corporation with a mission centered on longevity science, healthspan, and accessible longevity education.
Why NOVOS is a Public Benefit Corporation →Find your starting point
Choose support based on your current priority.
NOVOS products serve different roles—from a broad longevity foundation to targeted support and measurement.
- Foundational longevity supportStart with NOVOS Core, designed around the 12 Hallmarks and studied as a complete formulation.
- Sleep and recoveryExplore targeted support and guidance for sleep quality and recovery.
- Healthy metabolismExplore support for metabolic health, glucose regulation, and healthy body composition.
- Skin and cellular supportExplore support for skin health and cellular aging biology.
What the evidence supports—and what remains unknown.
What the evidence supports
- The finished Core formula produced favorable placebo-adjusted effects across three fundamental measures of vascular function.
- The complete formulation produced favorable lifespan and functional-health findings in aged-animal research.
- Preliminary human research found a lower DunedinPACE result at follow-up in 8 of 11 Core + Boost participants.
What remains unknown
- Whether the vascular findings translate into fewer clinical events or longer human lifespan.
- Whether Core will have similar outstanding effects on other organ systems beyond cardiovascular.
- Whether the preliminary biological age testing will translate or replicate in larger placebo-controlled human studies.
The evidence is meaningful—and its limits should remain visible.
Review the complete research →Healthspan should be rigorously studied, not merely marketed.
Explore the research, the formulation, and the tools NOVOS has built to support a longer, healthier life.
These statements have not been evaluated by the Food and Drug Administration. These products and information are not intended to diagnose, treat, cure, or prevent any disease.